Replimune Group Inc (REPL)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.08B
Last updated: Nov 17, 2026 at 11:06 AM ET
Replimune Group Inc (REPL) Stock Forecast
Analysts expect Replimune Group (REPL) to earn -$2.05 per share in the fiscal year ending Mar 31, 2027, on revenue of $34.37M. Of 8 analysts, 7 rate the stock Buy or Strong Buy, 0 Hold and 1 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Mar 31, 2027 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 8 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 88% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 25.0% |
| Buy | 5 | 62.5% |
| Hold | 0 | 0.0% |
| Sell | 1 | 12.5% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 8
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 469.0%.
- Fiscal year ending Mar 31, 2027
- -$2.05
- EPS consensus, revenue $34.37M
- Fiscal year ending Mar 31, 2028
- -$0.67
- EPS consensus, revenue $195.55M
- Next report
- Feb 1, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Mar 31, 2027 | -$2.05 | -$2.16 to -$1.92 | 4 | $34.37M | $2.00M to $75.00M | 7 |
| Mar 31, 2028 | -$0.67 | -$1.16 to $0.43 | 4 | $195.55M | $24.30M to $461.10M | 7 |
Quarterly Estimates
The EPS consensus falls from -$0.47 for the quarter ending Dec 31, 2026 to -$0.61 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.47 | -$0.49 to -$0.45 | 4 | $7.19M | N/A | 7 |
| Mar 31, 2027 | -$0.61 | -$0.82 to -$0.43 | 9 | $28.09M | $1.96M to $66.15M | 8 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 4 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Mar 31, 2027 | 1 | 0 |
| Fiscal year ending Mar 31, 2028 | 2 | 0 |
| Quarter ending Dec 31, 2026 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Mar 31, 2027 has improved from -$2.14.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Mar 31, 2027 | -$2.05 | -$3.01 | -$3.01 | -$2.98 | -$2.14 | N/A |
| Fiscal year ending Mar 31, 2028 | -$0.67 | -$1.82 | -$1.82 | -$2.04 | -$1.27 | N/A |
| Quarter ending Dec 31, 2026 | -$0.47 | -$0.76 | -$0.76 | -$0.79 | -$0.56 | N/A |
Frequently Asked Questions About REPL
What is the REPL stock forecast?
Consensus analyst estimates put Replimune Group's EPS at -$2.05 for the fiscal year ending Mar 31, 2027, on revenue of $34.37M. The consensus rating from 8 analysts is Buy.
How do analysts rate REPL stock?
Of 8 analysts covering Replimune Group, 2 rate it Strong Buy, 5 Buy, 0 Hold, 1 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from REPL next year?
For the fiscal year ending Mar 31, 2027, the consensus EPS estimate is -$2.05, with estimates from -$2.16 to -$1.92 from 4 analysts. For the fiscal year ending Mar 31, 2028, the consensus EPS estimate is -$0.67, with estimates from -$1.16 to $0.43 from 4 analysts.
What revenue do analysts expect from Replimune Group next year?
For the fiscal year ending Mar 31, 2027, the consensus revenue estimate is $34.37M, with estimates from $2.00M to $75.00M. For the fiscal year ending Mar 31, 2028, the consensus revenue estimate is $195.55M, with estimates from $24.30M to $461.10M.
How many analysts cover REPL?
8 analysts rate Replimune Group stock, and 4 analysts estimate its EPS for the fiscal year ending Mar 31, 2027.
REPL pages: Overview, Earnings, Forecast, Financials, Competitors